Search Results
Dec 10, 2025, 10:09 ET Không gian tinh tế của LEPAS L8: Nơi trú ẩn an yên cho lối sống đề cao cảm xúc
rộng rãi cùng ghế gập phẳng dễ dàng tạo nên khu vực thư giãn rộng mở. Cửa sổ trời toàn cảnh mở ra tầm nhìn rõ ràng, không giới hạn — không cần lều trại — chỉ cần ngẩng đầu là có thể thưởng thức bầu trời sao lãng mạn. Mở bàn gấp phía sau và góc cà phê di động của riêng bạn lập tức hiện ra. Trong
More news about: LEPAS
Dec 01, 2025, 06:41 ET Centrus Energy Announces Uplisting to the New York Stock Exchange
BETHESDA, Md., Dec. 1, 2025 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) today announced that the company has been approved for uplisting to the New York Stock Exchange (NYSE) from the NYSE American (NYSE American). As a
More news about: Centrus Energy Corp.
Nov 20, 2025, 09:52 ET Orlando's Holiday Celebrations Kick Off with 70 Days of Festivities
Dazzling Nights at Harry P. Leu Gardens (Nov. 28 - Jan. 4) blooms with a million sparkling lights and shining forests.
More news about: Visit Orlando
Nov 10, 2025, 10:00 ET Enveniam Signs Agreement with LIS Technologies Inc. to Serve as Lead Project Integrator for New Laser-Based Uranium Enrichment Facility
the potential to be deployed with highly competitive capital and operational costs. L.I.S.T is optimized for LEU (Low Enriched Uranium) for existing civilian nuclear power plants, High-Assay LEU (HALEU) for the next generation of Small Modular Reactors (SMR) and Microreactors, the production of stable
More news about: Enveniam
Nov 10, 2025, 03:30 ET Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
has shown tumour infiltration by LEU011 cells. To date, treatment with LEU011 has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple patients treated with the lowest dose of LEU011. Dose-escalation in the AERIAL trial
More news about: Leucid Bio
Nov 06, 2025, 08:14 ET Centrus Announces "At-the-Market" Equity Offering Program
disruptions; the imposition of tariffs and/or sanctions that impact our ability to obtain, deliver, transport, or sell LEU or the SWU and natural uranium hexafluoride components of LEU delivered to us under the TENEX Supply Contract or other supply contracts or make related payments or deliveries of natural
More news about: Centrus Energy Corp.
Nov 05, 2025, 17:04 ET Centrus Reports Third Quarter 2025 Results
in contingent LEU sales commitments, with $2.1 billion of the total under definitive agreements and $0.2 billion of the total subject to entering into definitive agreements, in support of potential construction of LEU production capacity at the Piketon, Ohio facility. The contingent LEU sales commitments
More news about: Centrus Energy Corp.
Oct 31, 2025, 03:00 ET Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology
in Taiwan, announced the signing of a License Agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN's proprietary Val-Leu-Lys (VLK) linker technology in CDMO services worldwide. RIN's VLK linker has demonstrated superior anti-tumor efficacy and high
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax und RIN unterzeichnen Lizenzvereinbarung zur Förderung der ADC-Entwicklung unter Verwendung der proprietären Linker-Technologie von RIN
Unterzeichnung einer Lizenzvereinbarung mit dem japanischen Unternehmen RIN Institute Inc. bekannt, die Mycenax das Recht einräumt, die proprietäre Val-Leu-Lys (VLK)-Linker-Technologie von RIN weltweit für CDMO-Dienstleistungen zu nutzen. Der VLK-Linker von RIN hat eine überlegene
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax et RIN signent un accord de licence pour faire progresser le développement d'ADC à l'aide de la technologie de liaison exclusive de RIN
signature d'un accord de licence avec RIN Institute Inc. basé au Japon, accordant à Mycenax les droits d'application de la technologie de linker Val-Leu-Lys (VLK) exclusive de RIN dans les services CDMO du monde entier. Le linker VLK de RIN a démontré une efficacité anti-tumorale
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax y RIN firman un acuerdo de licencia para impulsar el desarrollo de ADC
anunció la firma de un acuerdo de licencia con RIN Institute Inc. con sede en Japón, otorgando a Mycenax derechos para aplicar la tecnología de enlace Val-Leu-Lys (VLK) patentada de RIN en servicios CDMO en todo el mundo. El ligador VLK de RIN ha demostrado una eficacia antitumoral superior
More news about: Mycenax Biotech Inc.
Oct 15, 2025, 06:30 ET Centrus to Webcast Conference Call on November 6 at 8:30 a.m. ET
BETHESDA, Md., Oct. 15, 2025 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) will broadcast its quarterly conference call with shareholders and the financial community over the Internet on Thursday, November 6, 2025, at 8:30
More news about: Centrus Energy Corp.
Sep 25, 2025, 04:00 ET Centrus Details Plans to Add At Least 300 New Jobs in Southern Ohio With Multi-Billion-Dollar Investment
while retaining 127 existing jobs, boosting Low-Enriched Uranium (LEU) and High-Assay, Low-Enriched Uranium (HALEU) production. The size and scope of the expansion depend on federal funding decisions from the U.S. Department of Energy for LEU and HALEU, and a large-scale expansion would represent a multi-billion-dollar
More news about: Centrus Energy Corp.